Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Polypharmacy

NICE tackles complex health issues for people with multimorbidity

Guidance sets out principles for tailored care approach for patients with two or more long-term health conditions.

The National Institute for Health and Care Excellence (NICE) has issued draft guidance to help clinicians manage patients affected by multiple long-term health conditions.

The draft guidelines for the clinical assessment and management of multimorbidity set out principles for optimising care for people with two or more long-term health conditions. These include identifying medicines with a higher risk of unwanted side effects or potential drug interactions; stopping treatment if it is considered to be of limited benefit or a risk; and offering alternative, non-pharmacological treatments where appropriate. The guidance recommends a tailored approach that puts the patient at the centre of decisions about their care.

NICE’s existing disease focused guidelines are geared towards patients with single conditions and do not take into account the wide range of other conditions that a patient might have, says Nina Barnett, a consultant pharmacist for older people at London North West Healthcare NHS Trust and NHS Specialist Pharmacy Services, and a member of the guideline development committee. “What we were trying to do was move from the concept of disease focused consultations towards patient focused consultations,” she says.

Nina Barnett, a consultant pharmacist for older people at London North West London Healthcare NHS Trust and NHS Specialist Pharmacy Service, and a member of the guideline development committee.

Nina Barnett, a consultant pharmacist for older people and a member of the guideline development committee, says NICE is trying to promote patient focused consultations

Patients with multimorbidity may be affected by clinical interactions between conditions and the drugs used to treat them, explains Barnett. She says that patients should be treated as individuals in terms of how their disease affects their health and their well being. Healthcare professionals should “support a collaborative discussion that helps the patient prioritise for themselves what is the most important thing for them”.

“We want patients to leave the consultation thinking, ‘I have been listened to, my concerns have been addressed and my medicines are now working better for me’,” she says. “It’s not really about what I think is the best medicine for you. It’s about what you want from your health and well being and how I as a clinician contribute to that through tailored medication review.”

The guidance says a tailored approach should be taken to care for patients with multimorbidity who are prescribed 15 or more regular medicines, because they are likely to be at higher risk of adverse events and drug interactions, and considered for patients prescribed 10 to 14 regular medicines, or fewer than 10 regular medicines if they are at particular risk of adverse events.

Patients with multimorbidity can be identified opportunistically during routine care or proactively using electronic health records, NICE states.

The number of people with three or more long-term health conditions is predicted to rise from 1.9 million in 2008 to 2.9 million in 2018. Such patients often struggle to manage their treatments or day-to-day activities, receive care from multiple services, have both long-term physical and mental health conditions, are at risk of falls, and frequently seek unplanned or emergency care. The average health and social care costs for these patients are estimated at around £7,700 per year.

The consultation is open until 12 May 2016, and the final guideline is expected to be published in September 2016.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200947

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • NICE office logo
  • NICE office logo

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.